AI In Genomics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global AI In Genomics Market Trends and Insights

Genomic Data Explosion Outpacing Manual Interpretation

A single whole-genome sequence can generate 200 GB to 300 GB of raw data, and annual genomic data output now runs into tens of exabytes globally. That data load is growing faster than manual analyst teams can review it, so the AI in genomics market is increasingly tied to interpretation speed rather than to data generation alone. This shift also favors vendors that combine algorithms with large, labeled, clinically validated variant libraries, because curation quality matters as much as model design once throughput becomes the constraint. SeqOne’s acquisition of Congenica in September 2025 reflected that logic, as the combined platform brought AI sequencing analytics together with a clinical decision library derived from the Wellcome Sanger ecosystem. The combined operation processed more than 200,000 patient genomic analyses in 2025, which was a 3-fold increase over 2024 and shows how fast scaled interpretation platforms are moving into routine use. In practical terms, the AI in genomics market now rewards data curation depth, case volume, and workflow automation more than stand-alone model claims.

Precision Medicine Scaling Across Oncology and Rare Disease

The AI in genomics market is seeing stronger demand from precision medicine, especially where oncology and rare disease programs now rely on the same interpretation stack. A 2025 study in Clinical and Experimental Medicine found that an autonomous AI agent that combined histopathology and genomics reached 91% accuracy for microsatellite instability diagnosis, which is a key biomarker for immunotherapy selection. That result matters because it supports the use of unified models across tissue, molecular, and clinical data rather than isolated decision tools. In rare disease, GeneDx reported preliminary 2025 revenue of USD 427 million, up 41% year over year, while exome and genome revenue grew 54% as genomic newborn screening expanded through state-backed programs^{[1]GeneDx, “GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance,” Business Wire, businesswire.com}. Those two care pathways are no longer developing in isolation, and that is widening the addressable demand base for the AI in genomics market. The same operating model that supports therapy matching in oncology can also support fast diagnosis in pediatric and inherited disorders.

AI-Led Drug Discovery Shortening Hypothesis Cycles

Drug discovery remains one of the clearest spending channels for the AI in genomics market, because AI is reducing the time between target hypothesis and candidate design. Profluent’s AI foundation models were trained on large recombinase datasets and can design site-specific enzymes for exact genomic targets, which enabled Eli Lilly to enter a collaboration worth up to USD 2.25 billion in April 2026. Illumina’s Alliance for Genomic Discovery expanded to 312,000 paired whole genomes and clinical records in March 2026 after Regeneron Genetics Center joined as the tenth member, which shows the scale of data infrastructure feeding these discovery systems. Tempus AI also stated in early 2026 that it had active contracts with 19 of the top 20 pharmaceutical companies and more than USD 2 billion in signed data and applications contracts. These partnerships show that capital is moving beyond single assets and into repeatable data and model platforms. The AI in genomics market therefore gains not only from molecule design, but also from proprietary data flywheels that become harder for smaller competitors to match.

Falling Sequencing Costs Widening Multi-Omic Adoption

Lower sequencing costs are expanding the practical use cases for the AI in genomics market, because more routine testing means more phenotypic and longitudinal data for model training. Illumina stated in February 2026 that TruPath Genome reduced workflow complexity by removing traditional library preparation and supported output of 16 whole genomes per day. Once sequencing becomes easier to run in everyday clinical settings, data diversity improves, and that strengthens downstream AI performance across variant interpretation and patient stratification. The effect is not limited to volume, because lower-cost workflows also make multi-omic studies more feasible across research, translational medicine, and clinical diagnostics. This creates a reinforcing cycle where cheaper sequencing widens access, wider access improves training data, and better models then increase the value of additional testing. In that environment, the AI in genomics market benefits from both cost reduction upstream and higher interpretation value downstream.

Data Privacy And Clinical AI Compliance Burden

The AI in genomics market faces a real regulatory barrier in Europe, where the EU AI Act treats genomic IVD systems in higher classes as high-risk AI systems. That framework requires risk management, technical documentation, human oversight, and cybersecurity controls, and full provisions for high-risk systems take effect from August 2027. The burden is heavier for vendors that update models continuously, because documentation must track material model changes rather than cover the entire platform once. France’s national strategy for artificial intelligence and health data, published in 2025, also ties deployment more closely to secondary-use governance and interoperable health data rules. Those rules favor hybrid and locally controlled architectures, which adds cost and slows scale for smaller companies in the AI in genomics market. Compliance therefore acts as a market filter, not because the technology is weak, but because commercialization is becoming more documentation-heavy^{[2]Anja Segschneider, “AI-Act: Regulierung von KI im Gesundheitswesen,” BIOPRO Baden-Württemberg GmbH, bio-pro.de}.

Scarcity of AI-Genomics Talent and Curated Labels

The AI in genomics market is also constrained by a shortage of teams that can combine clinical genomics, machine learning engineering, and production-grade data curation. Training data remains uneven, especially for splice events, structural variants, and deep intronic changes that are less represented in standard benchmark sets. A 2025 study in npj Genomic Medicine found substantial discordance between AlphaMissense outputs and clinical-grade curation in a rare-disease cohort, with precision of 32.9% for expert-curated pathogenic variants. That result shows why algorithm gains alone do not remove the need for curated clinical labels and domain-specific review. The AI in genomics market therefore gives a durable advantage to companies with proprietary case libraries, such as GeneDx and Tempus, because data quality and annotation depth still shape model performance at scale. This slows late entrants, especially where academic tools still need additional labeling work before they can operate reliably in clinical production.

Segment Analysis

By Component: Software Anchors Revenue While Services Accelerate

Software captured 42.1% of revenue in 2025, which made it the largest component in the AI in genomics market. The segment covers variant interpretation platforms, bioinformatics pipelines, clinical decision-support tools, and genomic foundation model APIs. Its lead position shows that the value stack is moving away from instruments and toward interpretation layers that can be sold on recurring terms. The AI in genomics market is therefore rewarding cloud-native software models that turn analytic logic into a repeatable revenue stream. QIAGEN’s May 2025 acquisition of Genoox, valued at USD 70 million to USD 80 million, confirmed this direction by adding the Franklin AI cloud platform to its Digital Insights portfolio. Franklin was active in more than 4,000 healthcare organizations across 50 countries and had supported more than 750,000 case interpretations at the time of the deal.

Services is the fastest-growing component, with a projected CAGR of 42.87% from 2026 to 2031. That pace reflects how much implementation, validation, and ongoing model maintenance matter once AI tools enter regulated environments. The AI in genomics market increasingly depends on professional services because laboratories and health systems often need support for integration, audit trails, and post-deployment tuning. Hardware remains the slowest-growing component, but it still matters in throughput-heavy workflows where compute performance shapes turnaround time. NVIDIA stated in March 2025 that Parabricks v4.5 reduced whole-genome germline analysis to under 8 minutes using 4 GPUs and added support for Blackwell architecture. That matters because software gains are strongest when labs can also process data at scale without long compute bottlenecks. Over time, the AI in genomics industry is likely to see more end-to-end contracts that bundle software, implementation services, and hardware acceleration into a single operating model. Those bundled deals raise switching costs and can stretch customer lifetime value well beyond an initial software subscription.

By Technology: Machine Learning Dominates While NLP Reshapes the Interface Layer

Machine learning held 63.18% of revenue in 2026, which kept it at the center of the AI in genomics market. Machine learning supports variant-effect prediction, polygenic risk scoring, biomarker classification, and other core tasks across research and clinical use. Classical methods such as gradient boosting and random forests still fit smaller and lower-dimensional clinical datasets well. Deep learning is more useful when the workflow involves large multi-omic inputs and higher-dimensional feature fusion. A systematic review in Clinical and Experimental Medicine reported that graph neural networks and attention-based models delivered strong performance in multi-omic oncology settings. That mix means the AI in genomics market is not moving toward a single model architecture, but toward a layered toolkit where older and newer methods coexist.

Natural language processing is the fastest-growing technology, with a projected CAGR of 43.18% through 2031. That growth comes from foundation model architectures that can read clinical notes, scientific literature, and variant databases in the same workflow. Tempus One added GenAI capabilities in January 2025 that supported patient timeline synthesis, prior authorization assistance, and querying across large volumes of unstructured documents. In the AI in genomics market, this moves NLP from a background enrichment role into the main clinical interface layer. Computer vision also retains a meaningful role in spatial multi-omic and digital pathology workflows, especially where image and molecular data need to be read together. Other methods, including reinforcement learning for design tasks and Bayesian methods for uncertainty handling, are still smaller parts of the mix but continue to widen the technical base of the AI in genomics market.

By Functionality: Sequencing Workflows Define Market Gravity

Genome sequencing represented 44.19% of revenue in 2026, which made it the largest functionality and fastest segment with 42.34% CAGR through 2031 in the AI in genomics market. That share reflects more than raw data generation, because AI now sits inside basecalling, alignment, variant calling, and quality scoring within the sequencing workflow itself. The AI in genomics market therefore draws a large part of its value from software layers that operate before formal interpretation even begins. Oxford Nanopore stated that its Dorado basecaller uses LSTM and transformer architectures for nanopore signal processing, runs on NVIDIA GPUs, processes hundreds of millions of signal samples per second, and achieves below 1% error from a single DNA strand. That kind of embedded AI raises the performance baseline for sequencing-led workflows. It also makes sequencing functionality harder to separate from software functionality in commercial terms.

Gene editing remained the second-largest functionality in the source draft, and its momentum is tied to AI-designed enzyme platforms. Profluent’s recombinase work, licensed by Eli Lilly in April 2026, shows how AI is extending editing beyond the insertion limits that constrain earlier approaches. Clinical workflow functionality is also moving higher in the revenue mix as automated prioritization tools reduce analyst hours in rare-disease review. A September 2025 clinical evaluation on medRxiv reported that SeqOne’s DiagAI identified causal variants in 94.9% of cases when HPO terms were integrated, and that 74% of top-listed variants were diagnostic. Predictive genetic testing is an emerging commercial frontier for the AI in genomics market, especially where preventive whole-genome sequencing is moving closer to health-plan settings. Illumina’s March 2026 consortium with Veritas Genetics supports that shift toward wider preventive use.

By Application: Drug Discovery Leads, Precision Medicine Sets the Pace

Drug discovery and development held 34.41% of revenue in 2025, which made it the largest application in the AI in genomics market. That lead reflects sustained pharma spending on AI-assisted target identification, lead optimization, and biomarker development. Tempus AI stated in early 2026 that 19 of the top 20 pharmaceutical companies had active data or application partnerships with the company. The same investor materials reported more than USD 2 billion in signed data and applications contracts, which shows how important platform access has become to pipeline strategy. The AI in genomics market is therefore being shaped by long-cycle platform relationships, not only by one-off software licenses. In that setting, companies that control curated data and real clinical workflows are gaining stronger bargaining power with pharma customers.

Precision medicine is the fastest-growing application, with a projected CAGR of 43.69% from 2026 to 2031. The demand driver is wider than oncology alone, because multi-disease molecular profiling is becoming a more practical preventive and diagnostic tool. A 2025 review in Clinical and Experimental Medicine cited federated learning frameworks that improved immunotherapy-response prediction by 30% across 17 institutions without pooling underlying data. That result matters because it shows the AI in genomics market can scale even in fragmented health systems where direct data pooling is difficult. Clinical diagnostics, agriculture, animal research, and other applications fill the remaining demand base. As those areas expand, the AI in genomics market gains a broader customer mix and becomes less dependent on a single vertical. The AI in genomics industry also benefits from this spread because demand is coming from both high-value clinical use and adjacent biological research workflows.

By Deployment Model: Cloud Leads While Hybrid Architecture Reshapes Delivery

Cloud-based deployment held 46.18% of revenue in 2026, which kept it as the largest delivery model in the AI in genomics market. Cloud platforms fit research and pharma users well because they simplify collaboration, scale compute resources, and support multi-site access. DNAnexus stated in September 2025 that its platform managed more than 125 petabytes of clinical, genomic, proteomic, and multiomic data across more than 60,000 registered users in 48 countries. The same announcement showed DNAnexus extending into point-of-care delivery through integration with Oracle Health EHR systems. That kind of expansion reinforces the role of cloud delivery in large research networks and commercial life sciences accounts. It also supports the AI in genomics market where shared data access matters more than local residency controls.

Hybrid deployment is the fastest-growing model, with a projected CAGR of 44.11% through 2031. The AI in genomics market is moving in that direction because regulated customers often need patient data to stay on-premise while still using cloud-based inference or orchestration tools. The EU AI Act and related European health data governance frameworks are pushing customers toward this design logic. France’s health data strategy, published in 2025, adds to this by emphasizing governance, interoperability, and secondary-use controls that hybrid systems can support more easily than pure cloud environments. On-premise deployment still matters in government genomics programs and in settings with more limited cloud infrastructure. Even so, the AI in genomics market is likely to see hybrid architectures absorb more of those workloads over time because they balance compliance and scale more effectively.

By End User: Pharma and Biotech Drive Volume While Clinical Labs Set Growth Pace

Pharmaceutical and biotechnology companies held 38.22% of revenue in 2025, which made them the largest end-user group in the AI in genomics market. Their lead position reflects large data partnerships, drug discovery platform subscriptions, and demand for AI-enabled trial design and biomarker workflows. Illumina’s Alliance for Genomic Discovery included AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, and Novo Nordisk among its members in March 2026. That consortium shows how multi-omic data access is now treated as a core research input rather than a discretionary expense. Academic and research institutes remain important users because they generate training data and early workflow validation for the AI in genomics market. Their revenue contribution is still limited by grant cycles and procurement constraints. Even so, they continue to shape the long-term direction of model development and data diversity.

Clinical laboratories and diagnostic centers are the fastest-growing end-user group, with a projected CAGR of 42.41% from 2026 to 2031. This reflects rising demand for fast turnaround, automated prioritization, and integrated reporting in routine testing. GeneDx stated in January 2026 that its ultraRapid Genome Sequencing service could deliver actionable insights for NICU and PICU patients in as little as 48 hours. announced in February 2026 that 2 new U.S. integrated health system agreements were expected to add 60,000 analyses annually. Healthcare providers, including hospitals and health systems, are also becoming a stronger channel as reimbursement support for comprehensive profiling expands. Tempus reported in March 2026 that its advanced genomic profiling features identified actionable findings in 12% of patients that standard testing had missed. Those patterns show the AI in genomics market moving from research-led demand toward routine-testing demand. They also show why laboratory operations are becoming one of the most important adoption settings across the AI in genomics market.

Geography Analysis

North America held the largest regional position, with 38.52% share in 2025, and that reflects a mature base of sequencing capacity, commercial AI genomics platforms, and earlier reimbursement traction for advanced diagnostics. Tempus AI reported Q1 2026 revenue of USD 348.1 million, up 36.1% year over year, with hereditary testing volume growth of 54% and minimal residual disease test volume growth of more than 500%. Those operating figures show how the AI in genomics market is moving from specialist oncology settings toward broader clinical use in North America. The United States remains the regional center of commercial activity, while Canada signaled its intention in September 2025 to build sovereign genomic data and AI infrastructure through a national genomics strategy and precision health initiative.

Europe remains a major contributor to the AI in genomics market because it combines dense clinical genomics networks with a regulatory framework that increasingly shapes global product design. The EU AI Act is pushing vendors toward validated and auditable systems, and that favors platforms that can document model behavior and workflow controls in detail. The UK Cancer 2.0 program and wider clinical deployment activity across the region show that Europe is not only regulating AI genomics tools, but also expanding the use cases for them. reported in March 2026 that it ended 2025 with 528 core genomics customers across more than 90 countries, including new signings at the Royal Infirmary of Edinburgh, AZ Delta in Belgium, and Ruhr University Bochum in Germany^{[3]SOPHiA GENETICS, “SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results,” PR Newswire, prnewswire.com}. France’s 2025 strategy for artificial intelligence and health data also shows a clear policy push toward interoperable genomic data systems at scale.

Asia-Pacific is the fastest-growing region in the AI in genomics market, with a projected CAGR of 42.81% through 2031. The regional outlook is supported by national genome programs, a broader build-out of AI-native diagnostic infrastructure, and a rising need for local data resources that improve cross-ancestry performance. The AI in genomics market in Asia-Pacific also benefits from the simple fact that new capacity is being added from a lower installed base, which supports faster expansion than in mature regions. Australia and South Korea continue to add weight through national genome initiatives and hospital-linked sequencing programs, while other markets in the region are building out clinical and translational capacity. 

Middle East and Africa and South America remain smaller in current revenue terms, but both are moving further into the early commercial phase of adoption. stated in March 2026 that liquid biopsy adoption at King Abdullah International Medical Center in Saudi Arabia and platform use at Brazil’s Human Genome and Stem Cell Research Center show that deployment is broadening outside the main established regions.